Deneysel spinal kord hasarının geç döneminde melatonin ve melatonin+dexpanthenol kombine tedavisinin biyokimyasal, moleküler genetik ve histopatolojik değişkenlere etkisi
Küçük Resim Yok
Tarih
2021
Yazarlar
Dergi Başlığı
Dergi ISSN
Cilt Başlığı
Yayıncı
İnönü Üniversitesi
Erişim Hakkı
info:eu-repo/semantics/openAccess
Özet
Amaç: Sıçanlarda Deneysel Spinal Kord Hasarının Geç Döneminde Melatonin ve Melatonin-Dexpanthenol Kombine Tedavisinin Biyokimyasal, Moleküler Genetik ve Histopatolojik değişikliklere etkilerini göstermek. Materyal ve Metot: 42 adet Sprague Dawley dişi sıçan, her grupta 7 adet olmak üzere; Kontrol, Sham, SKH, SKH+Dex, SKH+Mel ve SKH+Dex+Mel grubu olarak 6 gruba ayrıldı. Periyodik olarak nörolojik muayeneleri yapıldı. 3.hafta sonunda ve tedavi bitiminde MR görüntülemeleri yapıldı. İlaç tedavi protokolü bitiminden sonra spinal kord doku örnekleri alınarak biyokimyasal, moleküler genetik, histopatolojik yöntemlerle analizler yapıldı. Bulgular: Biyokimyasal analizlerde Kontrol grubuna göre SKH, SKH+Dex ve SKH+Mel gruplarında artan GSH, SOD, MDA ve XO düzeyleri tespit edildi. Spinal kord hasarı ile birlikte yükselen GSH, SOD, MDA ve XO seviyeleri SKH+Dex+Mel grubunda Kontrol grubu düzeylerine kadar gerilemişti. Gen ifadesi analizlerinde hiçbir grupta gen ifadelerinde bir değişiklik tespit edilmedi. Radyolojik parametrelerden spinal kord volüm artışı tüm ilaç verilen tedavi gruplarında belirgin bir azalma göstermişti, T2 sinyal artışı sadece SKH+Dex+Mel grubunda anlamlı düzeyde azalmıştı. Ortalama MTS ölçümleri SKH+Dex ve SKH+Dex+Mel gruplarında son ölçümlerde anlamlı düzeyde daha iyi bulundu. Histopatolojik incelemede SKH grubunda travmaya bağlı ciddi patolojik hasar tespit edilmişken Mel ve Dex'in ayrı uygulamasının bu hasarı iyileştirdiği, Mel ve Dex in birlikte kombine tedavisinin ise hasarı daha da iyileştirici etki yaptığı tespit edildi. Sonuç: SKH'nın geç dönemindeki hasarın tedavisinde Mel+Dex kombine tedavisi ile klinik anlamda fayda sağlanabileceğini düşünmekteyiz. Anahtar Kelimeler: Spinal Kord Yaralanması, Dexpanthenol, Melatonin, Gen İfadesi, Sıçan
Aim: To show the effects of Melatonin and Melatonin-Dexpanthenol Combined Treatment on Biochemical, Molecular Genetic and Histopathological Changes in the Late Stage of Experimental Spinal Cord Injury in Rats. Material and Method: Forty-two Sprague Dawley female rats, 7 in each group; The control was divided into 6 groups as Sham, SCI, SCI+Dex, SCI+Mel and SCI+Dex+Mel. Neurological examinations were performed periodically. MRI scans were performed at the end of the 3rd week and at the end of the treatment. After the end of the drug treatment protocol, spinal cord tissue samples were taken and analyzed by biochemical, molecular genetic and histopathological methods. Results: In the biochemical analyzes, increased GSH, SOD, MDA and XO levels were detected in the SCI, SCI+Dex and SCI+Mel groups compared to the control group. The levels of GSH, SOD, MDA and XO, which increased with spinal cord damage, decreased to the levels of the control group in the SCI+Dex+Mel group. In gene expression analyzes, no changes in gene expressions were detected in any group. Considering the radiological parameters, the increase in spinal cord volume showed a significant decrease in all drug-administered treatment groups, while the increase in T2 signal decreased significantly only in the SCI+Dex+Mel group. Mean MTS measurements were significantly better in the SCI+Dex and SCI+Dex+Mel groups at the last measurements. In the histopathological examination, while severe pathological damage due to trauma was detected in the SCI group, it was determined that the application of Mel, Dex improved this damage, and the combined treatment of Mel and Dex together had a more restorative effect on the damage. Conclusion: In our study, we think that Mel+Dex combined therapy may provide clinical benefit in the treatment of this damage in the late phase of SCI. Key Words: Dexpanthenol, Gene Expression, Melatonin, Spinal Cord Injury, Rat
Aim: To show the effects of Melatonin and Melatonin-Dexpanthenol Combined Treatment on Biochemical, Molecular Genetic and Histopathological Changes in the Late Stage of Experimental Spinal Cord Injury in Rats. Material and Method: Forty-two Sprague Dawley female rats, 7 in each group; The control was divided into 6 groups as Sham, SCI, SCI+Dex, SCI+Mel and SCI+Dex+Mel. Neurological examinations were performed periodically. MRI scans were performed at the end of the 3rd week and at the end of the treatment. After the end of the drug treatment protocol, spinal cord tissue samples were taken and analyzed by biochemical, molecular genetic and histopathological methods. Results: In the biochemical analyzes, increased GSH, SOD, MDA and XO levels were detected in the SCI, SCI+Dex and SCI+Mel groups compared to the control group. The levels of GSH, SOD, MDA and XO, which increased with spinal cord damage, decreased to the levels of the control group in the SCI+Dex+Mel group. In gene expression analyzes, no changes in gene expressions were detected in any group. Considering the radiological parameters, the increase in spinal cord volume showed a significant decrease in all drug-administered treatment groups, while the increase in T2 signal decreased significantly only in the SCI+Dex+Mel group. Mean MTS measurements were significantly better in the SCI+Dex and SCI+Dex+Mel groups at the last measurements. In the histopathological examination, while severe pathological damage due to trauma was detected in the SCI group, it was determined that the application of Mel, Dex improved this damage, and the combined treatment of Mel and Dex together had a more restorative effect on the damage. Conclusion: In our study, we think that Mel+Dex combined therapy may provide clinical benefit in the treatment of this damage in the late phase of SCI. Key Words: Dexpanthenol, Gene Expression, Melatonin, Spinal Cord Injury, Rat
Açıklama
Anahtar Kelimeler
Genetik, Genetics
